INM Stock Analysis
IN
Uncovered
InMed Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The company is developing a pipeline of prescription-based products, including rare cannabinoids and novel cannabinoid analogs, targeting the treatment of diseases with unmet medical needs (Product Candidates). The Company’s segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceuticals products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 provides both neuroprotection and reduces intraocular pressure in the eye.